Know Cancer

forgot password

REN-1654 in Sciatica: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study in Subjects With Pain Due to Lumbosacral Radiculopathy

Phase 2
18 Years
55 Years
Open (Enrolling)
Sciatica, Herniated Disc, Radiculopathy

Thank you

Trial Information

REN-1654 in Sciatica: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study in Subjects With Pain Due to Lumbosacral Radiculopathy

This is a multi-center, randomized, double-blind, placebo-controlled study to determine the
efficacy and tolerability of REN-1654 in subjects with sciatica. After screening and
baseline clinical assessments, subjects will be randomly assigned to receive REN 1654 100 mg
or matching placebo, once daily for 3 weeks. Leg pain, back pain and other efficacy
measures will be assessed at 1 and 3 weeks after initiation of treatment. A subset of
patients will undergo analysis of blood levels of REN-1654 during the course of the study
(pharmacokinetics). Subjects will discontinue treatment after 3 weeks and return after a
further 3 weeks off therapy for a final clinical assessment 6 weeks after initiation of
treatment. If a subject does not return for follow-up, an effort will be made by telephone
to document their clinical status and whether other interventions have been made.

Inclusion Criteria:

- Males or females, ages 18 to 55, able and willing to provide written informed consent
to participate in the study.

- Able to read, understand and follow the study instructions, including completion of
pain intensity rating scales.

- Leg pain radiating to or below the knee in a dermatomal pattern, diagnosed as being
due to sciatica or lumbar or lumbosacral radiculopathy, the onset of which occurred 2
to 12 weeks prior to initiation of study treatment.

- Leg pain severity on a screening Categorical Pain Intensity Rating (for the prior 24
hour period) of at least 4, using an 11-point categorical pain intensity scale with 0
= no pain and 10 = worst pain imaginable.

- Leg pain on a screening Categorical Pain Intensity Rating rated as more severe than
back pain.

- Positive straight leg raising (SLR) test as defined in Appendix B of this protocol.

- Subjects who are compliant in maintaining a Pain Diary between screening and baseline
visits, and who record a 24-hour average Categorical Pain Intensity Rating score of
at least 4 or greater on at least 3 days during the week prior to baseline visit.

- Subject who can maintain stable pharmacologic treatments for sciatica symptoms taken
prior to dosing including analgesics, anti-inflammatory medications (e.g. NSAIDS),
antidepressants, anticonvulsants, anxiolytics, or muscle relaxants. Subjects must be
on stable doses of such medications for 2 weeks prior to the baseline visit, and
maintained on the same doses throughout the study. Medications taken on an as-needed
basis are permitted, and subjects will be asked to record daily usage of such
medications in the subject diary.

- Subjects who at screening are receiving adjunctive analgesic therapy such as
acupuncture or biofeedback should either discontinue it or establish a schedule of
treatments that will remain consistent for 2 weeks prior to the baseline visit, and
throughout the study.

- Subject with screening laboratory values within normal limits, or if abnormal must be
considered not clinically significant and in the opinion of the Investigator not to
place the subjects at risk.

- If female, must be post-menopausal, surgically sterile, not currently pregnant
(verified by a screening pregnancy test) or nursing, and using a reliable
contraception method such as intrauterine device (IUD), hormonal birth control pills,
or double barrier method (male condom, female condom or diaphragm with spermicidal

- If male, must agree to use double-barrier methods of contraception.

Exclusion Criteria:

- History of peripheral neuropathy or any other pain conditions with pain intensity
equal to or greater than the pain associated with sciatica.

- Motor loss in a muscle corresponding to the affected dermatome graded as more than

- History of cauda equina syndrome, symptomatic scoliosis, spondylolisthesis
(degenerative or isthmic), ankylosing spondylitis, rheumatoid arthritis or other
inflammatory arthropathies. Degenerative arthritis is allowed.

- History of hepatic, cardiovascular, renal, gastrointestinal, hematological,
neurological, endocrine (including diabetes), metabolic, pulmonary, immunological
(including HIV infection) or psychiatric disease that in the opinion of the
Investigator would pose a significant safety risk for a subject exposed to an
investigational compound such as REN-1654.

- History of the following ophthalmic disorders based upon general medical review at
the screening visit. Subjects will further undergo a screening ophthalmologic
assessment. Should any of the following be identified at the screening ophthalmologic
examination, the subject will be excluded from the study.

- Symptomatic cataract, resulting in any visual impairment (if a subject has been
diagnosed with cataract to a degree that the cataract interferes with daily
living and/or regarding which an ophthalmologist has recommended cataract

- Other vision-impairing disorders (if a subject is aware of any eye disorder that
has impaired vision, such as age-related macular degeneration, lazy eye
(amblyopia), double vision, or any optic nerve inflammation; presbyopia and
other non-pathological visual acuity deficits are not exclusionary);

- Glaucoma or history of ocular hypertension (intraocular pressures greater than
21 mmHg).

- Cognitive or psychiatric disorders that may diminish compliance with study
procedures, including maintenance of a daily pain diary and accurate dosing of study

- Subjects who, at time of enrollment, have requested for or been advised by their
physicians to receive local, regional, or spinal (articular, epidural, intrathecal or
nerve root block) injections of medications for pain treatment or surgical
intervention for their sciatica symptoms.

- Although subjects who report work-related injuries will be allowed to enroll,
subjects will be excluded if they are involved in litigation related to the current
episode of sciatica.

- Subjects with a screening creatinine laboratory value of ≥ 2.0 mg/dL.

- Screening liver enzyme results greater than the upper limit of the normal range

- Use of chemotherapy agents or history of cancer, other than basal cell carcinoma and
squamous cell carcinoma, within five years prior to the screening visit.

- History of drug or alcohol abuse within one year prior to screening.

- Use within 2 weeks before start of study investigational compound dosing at baseline
and through the end of the study of any investigational compound, any epidural,
intrathecal, or nerve root block agent, corticosteroids, etanercept or other
anti-TNF-α agent, topical anesthetics, or topical analgesics .

- Previous participation in another REN-1654 study.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training

Outcome Measure:

Leg Pain: Change in Average Daily 11-Point Categorical Pain Intensity Rating at the end of the 3-week treatment period

Principal Investigator

Randall W Moreadith, MD, PhD

Investigator Role:

Study Director

Investigator Affiliation:

Chief Medical Officer, Renovis, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

December 2003

Completion Date:

April 2005

Related Keywords:

  • Sciatica
  • Herniated Disc
  • Radiculopathy
  • Herniated nucleus pulposus
  • Lumbosacral radiculopathy
  • Anti-TNF alpha
  • Tumor necrosis factor alpha
  • Sciatica
  • Intervertebral Disk Displacement
  • Radiculopathy



Research Across America New York, New York  10021
Alabama Clinical Therapeutics Birmingham, Alabama  35235
Advanced Clinical Therapeutics, LLC Tuscon, Arizona  85712
Orthopaedic Spine Center at Stanford University Medical Center Stanford, California  94305
Mile High Research Center Denver, Colorado  80218
Clinical Research of West Florida Clearwater, Florida  33765
Renstar Medical Research, Inc. Ocala, Florida  34471
Suncoast Neuroscience Associates St. Petersburg, Florida  33701
Emory Orthopaedics and Spine Center Atlanta, Georgia  30329
Brigham & Women's Hospital, Pain Trials Center Boston, Massachusetts  02115
A&A Pain Institute of St. Louis St. Louis, Missouri  63141
Washington University School of Medicine, Pain Management Center St. Louis, Missouri  63110
Asheville Neurology Specialists, PA Asheville, North Carolina  28806
Wake Research Associates Raleigh, North Carolina  27612
The Cleveland Clinic Spine Institute Cleveland, Ohio  44195
Lehigh Valley Hospital Neurosciences and Pain Research Allentown, Pennsylvania  18103
Omega Medical Research Warwick, Rhode Island  02886
Central Texas Spine Institute Austin, Texas  78731
Advanced Clinical Research West Jordan, Utah  84088